Synthesis and characterization of silica nanoparticles from rice ashes coated with chitosan/cancer cell membrane for hepatocellular cancer treatment

Int J Biol Macromol. 2023 Feb 15:228:487-497. doi: 10.1016/j.ijbiomac.2022.12.235. Epub 2022 Dec 26.

Abstract

Dual pH-sensitive smart nanocarriers based on silica nanoparticles (SNPs) extracted from rice husk ashes (RHAs) to effectively inhibit liver cancer cell proliferation were investigated. The SNPs were coated with chitosan (CH) and loaded with doxorubicin (DOX), then functionalized with cell membrane (CM) for homologous targeting ability. The FTIR spectra showed an absorption wave number at 1083 cm-1 which confirmed the existence of the SiOSi group, ratifying that the nanocarriers belong to silica species. The Korsmeyer-Peppas kinetic model reported R2 values of 0.996 and 0.931 for pH = 5.4 and pH = 7.4, respectively, demonstrating pH-responsive behavior of the nanocarriers. The cytotoxicity test confirmed that the HepG2 cell line treated with different SNP-CH-CM concentrations had no detectable significant cell toxicity, however, SNP-CH-DOX-CM induced greater cell death. In vivo tests revealed that SNP-CH-DOX-CM suppressed liver cancer growth in nude mice, demonstrating high pharmaceutical capability. Histological examination of vital organs showed that the targeted drug delivery system (DDS) had minor in vivo toxicity. In the light of its high treatment efficacy and minimal side effects, the investigated DDS is promising for the therapy of liver cancer.

Keywords: Cell membrane; Chitosan; Drug delivery system; Rice husk ash; Silica.

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular* / drug therapy
  • Cell Membrane
  • Chitosan* / chemistry
  • Doxorubicin
  • Drug Carriers / chemistry
  • Drug Delivery Systems
  • Hydrogen-Ion Concentration
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / pathology
  • Mice
  • Mice, Nude
  • Nanoparticles* / chemistry
  • Oryza*
  • Silicon Dioxide / chemistry

Substances

  • Chitosan
  • Silicon Dioxide
  • Doxorubicin
  • Drug Carriers